EMEA Widening of acceptance limit [Regulatives / Guidelines]

posted by hiren379 – India, 2012-05-02 10:39 (5152 d 21:31 ago) – Posting: # 8486
Views: 5,034

Hello friends,
EMEA states below
"Those HVDP for which a wider difference in Cmax is considered clinically irrelevant based on a sound clinical justification can be assessed with a widened acceptance range."

Is it necessary to give the justification a priori in the protocol for no relevance of wider difference in Cmax. :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
178 visitors (0 registered, 178 guests [including 28 identified bots]).
Forum time: 08:10 CEST (Europe/Vienna)

There are no dangerous thoughts;
thinking itself is dangerous.    Hannah Arendt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5